ROBERT E. FALLON
Mr. Fallon is President and CEO of Phosplatin Therapeutics, a company he helped found. He is a highly respected manager with decades of global transactional and strategic leadership. He is former Chairman & CEO of a large publicly traded company, the Korea Exchange Bank, and prior to that he ran all of Asia-Pacific for J.P. Morgan Chase.
He holds a B.A. in mathematics from Ohio University, and an MBA from Harvard Business School. Mr. Fallon also serves as Chairman of CIEE, the Council on International Educational Exchange, and is a member of the Council on Foreign Relations.
Mr. Price is a co-founder of Phosplatin Therapeutics, and is responsible for strategy, finance and operations across the company's activities, which since inception have expanded to thirteen countries. He holds an A.B. from Princeton University, where he graduated summa cum laude and Phi Beta Kappa.
He has held numerous research and managerial roles in the NGO and non-profit sectors, and after making a career change earned an MBA with distinction from Columbia Business School, where he was a Chazen Society Fellow in International Business and focused on private equity and entrepreneurship. He has since led several investment rounds in early-stage biotechnology and energy assets.
José Jimeno, MD, Phd
Dr. José Jimeno is a seasoned medical oncologist, who also holds a PhD from the University of Barcelona, and is leading the clinical development of PT-112. He has had a focus in drug development for over twenty years. Formerly VP of Clinical and scientific Development at Pharmamar, he was responsible for the integrated development of Yondelis®, which is approved in the U.s., the e.u., japan, and more than 60 other countries for the treatment of ovarian cancer and sarcoma.
His prior industry roles Also include work at Farmitalia Carlo Erba and at US Biosciences, where he focused on novel compounds in the anthracycline and anti-metabolite therapeutic classes. Most recently, Dr. jimeno was co-founder and CEO of Pangaea Biotech, a cancer diagnostics company focused on personalized medicine, where he was involved in the development of the EGFR mutation diagnostic approved by the FDA for use in non-small cell lung cancer patients. Dr. Jimeno has published over 100 papers in peer review journals on cancer research, and is a Guest Lecturer in immunology at the University of Zaragoza, Spain.
Tyler D. Ames, PhD
Tyler is Vice President of Research at Phosplatin Therapeutics, and leads the company's translational research efforts globally across multiple institutions.
Dr. Ames received his B.S. with high distinction in Biology and Biotechnology from Worcester Polytechnic Institute, and earned his doctorate in Molecular, Cellular and Developmental Biology from Yale University, where he focused on nucleic acid biochemistry. Most recently he was a post-doctoral fellow at Univ. of California Berkeley, focusing on commercial applications of yeast genetics.
Richard A. Wing, phd
Dr. Wing joins the Phosplatin team as director of research and operations, responsible for supporting the management of the company's clinical and translational research and operations. He was previously a post-doctoral fellow at rockefeller university, and most recently served as associate consultant at defined health, a boutique life sciences consultancy.
He earned a b.s. degree summa cum laude from vassar college, and his phd in biochemistry from yale university.
Ms. Frances Bonham is VP of Finance and administration of phosplatin therapeutics, responsible for financial and administrative management, along with operational support. She has more than 25 years experience in the financial services industry, where she was a managing director at JP Morgan Chase, responsible for covering international clients. Most recently she worked in external affairs at the korea society in new york.
she earned her bachelors' degree from the university of michigan and her MBA from the thunderbird graduate school of global management.
Joseph A. Rosamilia
Joseph Rosamilia leads business development efforts at Phosplatin. Over the course of his career Joh has established and managed business development groups for global Fortune 100 institutions in New York, London, Tokyo and Osaka where he expanded multi-product business lines across new geographic regions. He has structured and negotiated complicated deal structures as well as traditional financial assets accounting for several billion dollars of transactional experience.
After earning an MBA from the Wharton school, Joh established a boutique advisory firm during which time he served the business development and finance needs at a number of early-stage private and OTC-traded public companies, as well as at a cross-border biotech investment fund. He also previosuly advised Phosplatin therapeutics on licensing and fund-raising overseas. He holds a BA degree from Colgate University where he studied organic and inorganic chemistry and majored in East Asian Studies.
Taylor YOung is director of strategic development at Phosplatin therapeutics, focusing on the company's development and commercialization strategies. Prior to joining the company, MRs. Young was a Senior Consultant in the Life Sciences group at Navigant Consulting, where she created and implemented innovative solutions to resolve commercial, clinical, and regulatory challenges across the drug development spectrum. She specialized in launch strategy, life cycle management, and business development & licensing opportunities in the rare disease and oncology therapeutic areas. Most recently, she was in Product Management at Willis Towers Watson where she focused on product strategy and managed a team of software engineers.
Mrs. Young graduated from the joint-degree Roy & Diana Vagelos Program in Life Sciences and Management at the University of Pennsylvania, with a BS in Economics from the Wharton School and a concentration in Molecular Biology from the College of Arts and Sciences.
Ms. Malavé serves as a research Associate at Phosplatin therapeutics, where she supports the R&D and strategic initiatives of the company.
She is a graduate of stanford university, with a B.S. degree in bioengineering. at stanford, Celina worked in a synthetic biology lab, was a teaching assistant for the ethics in bioengineering class, and was the women in STEM coordinator at the stanford women's community center. She is concurrently pursuing a graduate degree at columbia university in the m.s. program in bioethics.
Lucas A. De Breed, PhD
Dr. De Breed is an advisor at Phosplatin Therapeutics, supporting the team’s clinical strategy. He obtained his PhD from University College London, completing his doctoral research in molecular oncology at the London Research Institute of Cancer Research UK, studying the epigenetic regulation of key tumor suppressor genes.
He established the East Coast office of Deallus Consulting in New York, where he conducted clinical and pipeline strategy engagements for biotechnology and pharmaceutical clients. Dr. De Breed holds an MBA from the Stanford Graduate School of Business.